PURPOSE: To evaluate the activity and safety of the @entity1205 , @entity136 and bevacizumab combination, administered biweekly, in pretreated @entity1 with @entity1722 -negative @entity0 ( @entity0 ). @entity1 AND METHODS: @entity1 with @entity1722 -negative @entity0 , and disease progression after at least one prior line of chemotherapy, were treated with @entity1205 50  mg/m(2), @entity136 1,500  mg/m(2) and bevacizumab 10  mg/kg every 2  weeks. Bevacizumab was continued until disease progression. RESULTS: Forty-eight @entity1 have been enrolled. Their median age was 61  years, 95.8  % had a performance status 0-1, 83.3  % had hormone receptor-positive disease, and 47.9  % had received one prior line of chemotherapy. All @entity1 were evaluable for @entity137 and 45 for response. Partial response was achieved in 20 @entity1 [PR  =  44.4  %, 95  % confidence interval (CI) 29.9-59  %] and disease stabilization in 15 (33.3  %). The median progression-free survival was 7.1  months (95  % CI 4.7-9.5  months) and the median overall survival 21.1  months (95  % CI 10.3-31.9  months). Grade 3-4 @entity1398 occurred in 19 @entity1 (39.6  %) and @entity1398 in 2 (4.2  %). Most common grade 2-3 non-hematologic adverse events included @entity390 (10.4  %), @entity294 (10.5  %), @entity2359 (12.5  %) and @entity1295 (31.3  %), whereas grade 2 @entity548 and @entity101 occurred in 6.3 and 10.4  %, respectively. There were no grade 4 @entity1503 or toxic deaths. CONCLUSION: The combination of @entity1205 , @entity136 and bevacizumab has promising activity and manageable @entity137 as salvage chemotherapy for @entity1722 -negative @entity0 @entity1 .

@entity1205 , @entity136 and bevacizumab as salvage chemotherapy for @entity1722 -negative XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Women', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer', 'MBC'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['non-hematologic toxicities'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1722 :: ('2064', 'Gene') :: ['HER-2']
@entity0 :: (MESH:D001943,Disease) :: ['metastatic breast cancer']
